Reports from major pharmacy chains and news outlets

FDA Approves First-of-its-Kind At-Home FluMist Nasal Spray

Sep 20, 2024, 07:52 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self-administration or caregiver-administration. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. FluMist is licensed for individuals aged 2 to 49 and will be available through third-party pharmacies where users will complete a screening and eligibility assessment. The FDA's decision is part of a broader effort to expand consumer access to medicines and reduce healthcare costs and barriers.